Background Previous efficacy trials of SPf66 malaria vaccine have produced conflicting
results in different populations. We report a randomised double-blind trial of the SPf66 …

Effective, safe antimalarial vaccines have proved elusive. The synthetic polypeptide SPf66
vaccine is based on pre-erythrocytic and asexual blood-stage proteins of Plasmodium …

SPf66 malaria vaccine is a synthetic protein with aminoacid sequences derived from pre-
erythrocytic and asexual blood-stage proteins of Plasmodium falciparum. SPf66 was found …

The SPf66 synthetic vaccine is safe and partly efficacious against Plasmodium falciparum
malaria among children 1–5 years old. The estimated vaccine efficacy [VE] for all clinical …

Summary background Malaria control programmes need to protect young children, who
bear the brunt of malaria disease and death in Africa. The development of a vaccine is a …

Preclinical and clinical studies have established the safety and immunogenicity of the
chemically synthesised SPf66 malaria vaccine. The present study is a phase III randomised …

As part of the first trial of the SPf66 malaria vaccine in Africa, three randomized double-blind
placebo-controlled studies of SPf66 have been conducted in a highly endemic area of …

In the first phase III efficacy trial of the malaria vaccine SPf66 in Africa, MOIs in SPf66-and
placebo-vaccinated children were analyzed by polymerase chain reaction-restriction …

In the first field trial with synthetic malaria vaccine SPf66 in a large population naturally
exposed to malaria, 9957 persons> 1 year old and residing on the Colombian Pacific coast …

A crucial step has been made in the development of malaria vaccines. The first trial of SPf66
in Africa and the first outside Latin America has been completed in an area of very intense …